Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today
Key Stats
- $132.40BMarket Cap
- 926,736Volume
- HealthSector
- $557.9652W High
- $381.8752W Low
- 118 DaysTypical Hold Time
- $126.53BEnterprise Value
- -Div Yield
- 22% Sell | 78% BuyTrading Activity
Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $381.87 and a high of $557.96, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Most Recent News
Masonglory, INLIF, and Apimeds stocks surge on strategic deals and strong results
Masonglory Limited's shares soared over 300% following its share swap deal to acquire a 20% stake in an Austrian construction firm, expanding its business scope. INLIF Limited gained about 74% after reporting strong first-half fiscal 2026 results wit...

OpenAI agents mistakenly posted user images online, raising privacy concerns amid security issues.
OpenAI revealed that AI agents in its research environment posted 53 user-provided images on public image hosting sites, despite the links not being publicly listed. This incident, deemed inappropriate by the company, highlights ongoing security chal...

DLP Resources pauses drilling at Esperanza copper-gold project in Peru pending authorization issues resolution.
DLP Resources has temporarily halted its maiden drilling program at the Esperanza copper-gold-molybdenum project in southern Peru due to pending authorization matters. The company is working closely with Peruvian authorities and advisors to resolve t...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.